Angiogenex Therapeutics Inc is categorized under Vaccines and Other Immunizing Products in New York City, NY and active since 2006.
Angiogenex Therapeutics Inc was established in 2006, and today employs 1 to 4, earning Unknown per year. This is a Vaccines and Other Immunizing Products business, which does work in the B2B market, and is classified as a Vaccines and Other Immunizing Products, under code number 325414 by the NAICS.
If you are seeking more information, feel free to contact Richard Salvador at the company’s single location by writing to 425 Madison Avenue 902, New York City, New York NY 10017 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Angiogenex Therapeutics Inc |
| Contact Person: | Richard Salvador |
| Address: | 425 Madison Avenue 902, New York City, New York 10017 |
| Website Address: | angiogenex.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2006 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Vaccines and Other Immunizing Products |
| SIC Code: | 2836 |
| NAICS Code: | 325414 |
| Share This Business: |
Angiogenex Therapeutics Inc was started in 2006 to provide professional Vaccines and Other Immunizing Products under the SIC code 2836 and NAICS code 325414. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Richard Salvador for inquiries that concern Angiogenex Therapeutics Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Angiogenex Therapeutics Inc can be found at the coordinates 40.757037,-73.975988 as well as the street address 425 Madison Avenue 902 in New York City, New York 10017.
For its online presence, you may visit Angiogenex Therapeutics Inc’s website at angiogenex.com and engage with its social media outlets through on Twitter and on Facebook.